Health economic analysis: What do we need to know?

Authors

DOI:

https://doi.org/10.33448/rsd-v10i10.18527

Keywords:

Health economics; Scarce resources; Consequences examined; Costs.

Abstract

In the Health Technology Assessment (HTA), economic evaluations assessments are constantly used, as they are analysis techniques that comparatively assess two or more technologies/programs/actions through the systematic measurement of costs and their consequences. The aim of the article is to illustrate how the basic principles of health economics can be applied to decision-making in health through analysis techniques that provide information so that the allocation of resources is rational and transparent in times of budget constraints. This is becoming increasingly important as the demand for healthcare services increases and so do the costs associated with treatment. This article presents general definitions of economic valuation analysis techniques; It describes the main comprehensive economic assessments: cost-effectiveness, cost-utility, cost-minimization, and cost- effectiveness, provide information to be used to determine the best course of action, where the choice and use of health technologies can be prioritized.

References

Abad, F., Calbo, F., Zapater, P., Rodrıguez-Vilanova, F., Garcia-Perez, L. E., & Sacrista, J. (2000). Comparative pharmacoeconomic study of vancomycin and teicoplanin in intensive care patients. International Journal of Antimicrobial Agents, 15 (1), 65-71. 10.1016 / s0924-8579 (00) 00123-0.

Andrade, L. O. M. (2012). O papel da avaliação para a tomada de decisão na gestão de serviços de saúde. Ciência & Saúde Coletiva, 17, 829-837.

Almeida, A., Borba, J., & Flores, L. (2009). A utilização das informações de custos na gestão da saúde pública: um estudo preliminar em secretarias municipais de saúde do estado de Santa Catarina. Revista de Administração Pública, 43, 579-607.

Alonso, M. (1999). Custos no serviço público. Revista do Serviço Público, 50 (1), 37-63. https://doi.org/10.21874/rsp.v50i1.340.

Aminde, L., Dzudie, A., Mapoure, Y., Tantchou, J., & Veerman, J. L. (2021). Estimation and determinants of direct medical costs of ischaemic heart disease, stroke and hypertensive heart disease: evidence from two major hospitals in Cameroon. BMC Health Services Research, 21 (140), 1-13, 2021.

Argenta, C., Ferreira, M., Sander, G. B., & Moreira, L. B. (2011). Short-Term Therapy with Enoxaparin or Unfractionated Heparin for Venous Thromboembolism in Hospitalized Patients: Utilization Study and Cost-Minimization Analysis. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). VALUE IN HEALTH, 14, 589-592. 10.1016/j.jval.2011.05.01.

Astrid, L. (2012). A framework for assessing Health Economic Evaluation (HEE) quality appraisal instruments. BMC Health Services Research, 12 (253). 10.1186/1472-6963-12-253.

Angus, D., Linde-Zwirble, W., Clermont, G., Ball, D., Basson, B., Ely, W., Laterre, P.F., Vincent, J.L., Bernard, G., & Hout, B. (2003). Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Critical Care Med, 31 (1), 1-11. 10.1097/01.CCM.0000046067.70067.59.

Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., Azambuja, E., Aura, Claudia, G., Henry, D., Phuong, F., Karine, V., Veerle, A., Gursel, G., Aron, C., Tsai-Wang, H., Zsolt, C.P., Maria, D., Julien, T., Ling-Min, K., Georg, Sohn, J., Semiglazov, V., Lerzo, G., Palacova, M., Probachai, V., Pusztai, L., Untch, M., Gelber, D., & Piccart-Gebhart, M. (2012). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. The Lancet, 379(9816), 633 – 640. 10.1016/S0140-6736(11)61847-3.

Battista, R.N. (1996). Towards a paradigm for technology assessment. In: Peckham, M., & Smith, R. (Ed), The scientific basis of health services (p. 11-18). London: BMJPublishing Group.

Byford, S., McDaid, D., & Sefton, T. (2003). Because it’s worth it: A practical guide to conducting economic evaluations in the social welfare field. United Kingdom: Joseph Rowntree Foundation.

Constituição da República Federativa do Brasil de 1988. (1988). https://www.senado.leg.br/atividade/const/con1988/con1988_06.0 6.2017/art_196_.asp#:~:text=196.

Chalfin, D. (1998). Evidence-based medicine and cost-effectiveness analysis. Evidence-based critical care medicine. 14(3), 704-749.

Campolina, A., & Ciconelli, R. (2006). Quality of life and utility measures: clinical parameters for decision-making in health. Revista Panamericana de Salud Pública (Impresa) / Pan American Journal of Public Health (Impresa), 19, p. 128-136.

Contandriopoulos, A.P. (2006). Avaliando a institucionalização da avaliação. Ciência & Saúde Coletiva, 11 (3), 705-711.

Cox H., Laupland, K., & Manns, B. (2006). Economic evaluation in critical care medicine. Journal of Critical Care, 21, 117 – 124. 10.1016/j.jcrc.2006.02.003.

Centre for Epidemiology and Evidence. (2017). Commissioning Economic Evaluations: A Guide. Evidence and Evaluation Guidance Series, Population and Public Health Division. Sydney: NSW Ministry of Health. Retrieved from: https://www.health.nsw.gov.au/.

Cohen, D. R. (1984). Economic issues in infection control. Journal of Hospital infection, 5, 17-25.

Drummond M. F., Sculpher M. J., Torrance G. W., O’Brien B. J., & Stoddart G. L. (2005). Métodos de avaliação econômica de programas de saúde (2a ed.). Oxford: Oxford University Press.

da Silva Etges, A., Cruz, L. N., Notti, R. K., Neyeloff, J. L., Schlatter, R. P., Astigarraga, C. C., Falavigna, M., & Polanczyk, C. A. (2019). An 8-step framework for implementing time-driven activity-based costing in healthcare studies. The European journal of health economics: HEPAC : health economics in prevention and care, 20(8), 1133–1145. https://doi.org/10.1007/s10198-019-01085-8.

Eichler, H. G., Kong, S. X., Gerth, W. C., Mavros, P., & Jönsson, B. (2004). Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research, 7(5), 518–528. https://doi.org/10.1111/j.1524-4733.2004.75003.

Higgins, A. M., & Harris, A. H. (2012). Health Economic Methods: Cost-Minimization, Cost-effectiveness, Cost-Utility, and Cost-Benefit Evaluations. Critical Care Clin, 28, 11-24. 10.1016/j.ccc.2011.10.002.

Hoffmann, C., & Schulenburg, J.M. (2000). The influence of economic evaluation studies on decision making. A European survey. Health Policy, 52 (3), p. 179–192. https://www.journals.elsevier.com/health-policy.

Holmes, S., & Sunstein, C. (2016). The cost of rights: why liberty depends on taxes. New York: Norton, 2000. Resenha. 17 (2), p. 681-688.

Habicht, J.P., Victora, C.G., & Vaughan, J.P. (1999). Evaluation designs for adequacy, plausibility and probability of public health programme performance and impact. International Journal of Epidemiology, 28, p. 10–18.

Institute of Health Economics. (2000). A National List of Provincial Costs for Health Care: Canada 1997/8 (1ª ed.). Canadá: Institute of Health Economics.

Itria, Alexander. (2011). Análise e determinação de custos específicos e consequências econômico-sociais na incorporação da vacina contra meningite e doença meningocócica C conjugada na rotina do Programa Nacional de Imunização/PNI. 2011. Tese (Doutorado em Medicina Preventiva) - Faculdade de Medicina, Universidade de São Paulo, SP, Brasil.

Instituto Brasileiro De Geografia E Estatística. (2018). Projeção da População 2018: Número de habitantes do país deve parar de crescer em 2047. https://agenciadenoticias.ibge.gov.br/agencia-sala-de-imprensa/2013-agencia-de-noticias/releases/21837-projecao-da-populacao-2018-numero-de-habitantes-do-pais-deve-parar-de-crescer-em-2047.

Kaplan, R., & Porter, M. (2011). THE BIG IDEA How to Solve the Cost Crisis in Health Care The biggest problem with health care isn’t with insurance or politics. It is that we’re measuring the wrong things the wrong way. Harvard Business Review September. https://hbr.org/2011/09/how-to-solve-the-cost-crisis-in-health-care?referral=00060.

Krüger, T., Stuckler, D., & Basu, S. (2019). A economia desumana: porque mata a austeridade. Saúde Em Debate, 43 (120), 287-289. https://doi.org/10.1590/0103-1104201912022.

Kesselheim, A., Avorn, J., & Sarpatwari, A. (2016). The high cost of prescription drugs in the United States: origins and prospects for reform. Jama, 316 (8), p. 858-871. https://doi.org/10.1001/jama.2016.11237.

Kristensen F. B. (2009). Health technology assessment in Europe. Scandinavian journal of public health, 37(4), 335–339. https://doi.org/10.1177/1403494809105860.

Lessa, F., Caccavo, F., Curtis, S., Ouimet-Rathé, S., & Lemgruber, A. (2017). Strengthening and implementing health technology assessment and the decision-making process in the Region of the Americas. Rev Panam Salud Publica, 41 (165), 1-10. 10.26633/RPSP.2017.165.

Ministério da Saúde. (2013). Série ECOS Economia da Saúde para a Gestão do SUS: Banco de Preços em Saúde – BPS, Ministério da Saúde.

Ministério da Saúde. (2014). Diretrizes Metodológicas: Diretriz de Avaliação Econômica (2a ed.). Ministério da Saúde.

Manns, B., Taub, K., & Donaldson, C. (2000). Economic evaluation and end-stage renal disease: from basics to bedside. American Journal of Kidney Diseases, 36 (1), 12-28.

Marques, F., Penedones, A., Mendes, D., & Alves, C. (2016). A systematic review of observational studies evaluating costs of adverse drug reactions. Clinico Economics and outcomes research: CEOR, 8, 413. 10.2147/ceor.s115689.

Novaes, H. M. D. (2004). Pesquisa em, sobre e para os serviços de saúde: panorama internacional e questões para a pesquisa em saúde no Brasil. Cadernos de Saúde Pública (FIOCRUZ), 20 (2), 147-174.

Organização Pan-Americana da Saúde. (2021). Antimicrobial Resistance. https://www.paho.org/en/topics/antimicrobial-resistance.

Organização Pan-Americana da Saúde. (2017). Saúde nas Américas+, Edição de 2017. Resumo do panorama regional e perfil do Brasil. OPAS.

Organization for Economic Co-operation and Development. (2020). Health Expenditure. https://www.oecd.org/health/health-expenditure.htm.

Organization for Economic Co-operation and Development. (2019). Society at a Glance 2019: OECD Social Indicators. OECD Publishing. https://doi.org/10.1787/soc_glance-2019-en.

Park, M., Jit, M., & Wu, J. T. (2018). Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks. BMC medicine, 16(1), 139. https://doi.org/10.1186/s12916-018-1130-7.

Pinho, M., Veiga, P. (2009). Avaliação de custo-utilidade como mecanismo de alocação de recursos em saúde: revisão do debate. Cad. Saúde Pública, 25, 239-250. https://doi.org/10.1590/S0102-311X2009000200002.

Porter, M.E. (2010). Harvard/Business S: What is value in health care? N. Engl. J. Med, 363, 2477–2481. 10.1056/nejmp1011024.

Posso, M., Carles, M., Rué, M., Puig, T., & Bonfill, X. (2016). Cost-Effectiveness of Double Reading versus Single Reading of Mammograms in a Breast Cancer Screening Programme. PLOS ONE, 11 (7), 1-13. 10.1371/journal.pone.0159806.

Raikou, M., Briggs, A., Gray, A., & McGuire, A. (2000). Centre-specific or average unit costs in multi-centre studies? Some theory and simulation. Health Economics, 9, 191-198.

Russell, L. B., Gold, M. R., Siegel, J. E., Daniels, N., & Weinstein, M. C. (1996). The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA, 276(14), 1172–1177.

Robbins, L. (2007). An Essay on the Nature and significance of Economic Science Macmillan or CO.

Rosselli, D., Quirland-Lazo, C., Csanádi, M., Ruiz de Castilla, E. M., González, N. C., Valdés, J., Abicalaffe, C., Garzón, W., Leon, G., & Kaló, Z. (2017). HTA Implementation in Latin American Countries: Comparison of Current and Preferred Status. Value in health regional issues, 14, 20–27. https://doi.org/10.1016/j.vhri.2017.02.004.

Ribeiro, R., Stella, S., Zimerman, L., Pimentel, M., Rohde, L., & Polanczyk, C. (2010). Custo-efetividade de cardiodesfibriladores implantáveis no Brasil nos setores público e privado. Arquivos Brasileiros de Cardiologia, 95 (5), 577-586. http://www.arquivosonline.com.br.

Soarez P.C., & Novaes, H.M.D. (2017). Cost-effectiveness thresholds and the Brazilian Unified National Health System. Cad. Saúde Pública, 33(4). 01-05. 10.1590/0102-311X00040717.

Sanders, D., Neumann, J., Basu, A., Brock, W., Feeny, D., Krahn, M., Kuntz, M., Meltzer, D., Owens, D., Prosser, L., Salomon, J., Sculpher, M., Trikalinos, T., Russell, L., & S., Ganiats, T. (2016). Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA, 316 (10), 1093-1103. 10.1001/jama.2016.12195.

Saraiva, A., Rodrigues, A., Coimbra, C., Fantasia, M., & Nunes, R. (2018). Contabilidade de Gestão: Método de custeio e valorização de inventários e Valorização de Inventário. Edições Almedina, S.A.

Shorr, F. (2002). An update on cost-effectiveness analysis in critical care. Current Opinion in Critical Care, 1070–5295. https://doi.org/10.1097/00075198-200208000-00011.

Secoli, S.R., Nita, M.E., Ono-Nita, S.K., & Nobre, M. (2010). Avaliação de tecnologia em saúde: II. A análise de custo-efetividade. Arquivos de Gastroenterologia, 47 (4), 329-333.

Shrank, W., Rogstad, T., & Parekh, N. (2019). Waste in the US health care system: estimated costs and potential for savings. Jama, 322 (15), 1501-1509. https://doi.org/10.1001/jama.2019.13978.

Shiell, A., Donaldson, C., Mitton, C., & Currie, G. (2002). Epidemiol Community Health. Health economic evaluation, 56, 85-88. https://jech.bmj.com/.

Tesouro Nacional. (2018). Aspectos Fiscais da Saúde no Brasil. https://sisweb.tesouro.gov.br/apex/f?p=2501:9::::9:P9_ID_PUBLICACAO:28265.

Tanaka, O., & Tamaki, E.M. (2012). O papel da avaliação para a tomada de decisão na gestão de serviços de saúde. Ciência e Saúde Coletiva (Impresso), 17, 821-828.

Vieira, F.S., & Benevides, R.P. (2016). O direito à saúde no Brasil em tempos de crise econômica, ajuste fiscal e reforma implícita do Estado. Revista de Estudos e Pesquisas sobre as Américas, 10 (3), 01-28. http://dx.doi.org/10.21057/repam.v10i3.21860.

World Health Organization. (2021). Medicines. https://www.who.int/health-topics/medicines#tab=tab_3.

Xavier, R. (2019). Austeridade que mata: uma análise do impacto da crise política sobre os indicadores de Atenção Primária em Saúde no Estado de São Paulo. Dissertação (Mestrado em Ciências) - Programa de pós-graduação de Gestão de Políticas Públicas, Universidade de São Paulo, SP, Brasil.

Yu, Y. R., Abbas, P. I., Smith, C. M., Carberry, K. E., Ren, H., Patel, B., Nuchtern, J. G., & Lopez, M. E. (2016). Time-driven activity-based costing to identify opportunities for cost reduction in pediatric appendectomy. Journal of pediatric surgery, 51(12), 1962–1966. https://doi.org/10.1016/j.jpedsurg.2016.09.019.

Published

05/08/2021

How to Cite

ROCHA, C. A. .; ROSSI, T. A. .; BOA SORTE, N. C. A. .; MACIEL , R. R. B. T. . Health economic analysis: What do we need to know? . Research, Society and Development, [S. l.], v. 10, n. 10, p. e49101018527, 2021. DOI: 10.33448/rsd-v10i10.18527. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/18527. Acesso em: 20 oct. 2021.

Issue

Section

Review Article